The development and characterization of an E. coli O25B bioconjugate vaccine.
Bioconjugate vaccine
Escherichia coli
Physicochemical characterization
ST131
Serotype O25B
Journal
Glycoconjugate journal
ISSN: 1573-4986
Titre abrégé: Glycoconj J
Pays: United States
ID NLM: 8603310
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
28
12
2020
accepted:
24
02
2021
revised:
18
02
2021
pubmed:
18
3
2021
medline:
25
2
2022
entrez:
17
3
2021
Statut:
ppublish
Résumé
Extraintestinal pathogenic Escherichia coli (ExPEC) cause a wide range of clinical diseases such as bacteremia and urinary tract infections. The increase of multidrug resistant ExPEC strains is becoming a major concern for the treatment of these infections and E. coli has been identified as a critical priority pathogen by the WHO. Therefore, the development of vaccines has become increasingly important, with the surface lipopolysaccharide constituting a promising vaccine target. This study presents genetic and structural analysis of clinical urine isolates from Switzerland belonging to the serotype O25. Approximately 75% of these isolates were shown to correspond to the substructure O25B only recently described in an emerging clone of E. coli sequence type 131. To address the high occurrence of O25B in clinical isolates, an O25B glycoconjugate vaccine was prepared using an E. coli glycosylation system. The O antigen cluster was integrated into the genome of E. coli W3110, thereby generating an E. coli strain able to synthesize the O25B polysaccharide on a carrier lipid. The polysaccharide was enzymatically conjugated to specific asparagine side chains of the carrier protein exotoxin A (EPA) of Pseudomonas aeruginosa by the PglB oligosaccharyltransferase from Campylobacter jejuni. Detailed characterization of the O25B-EPA conjugate by use of physicochemical methods including NMR and GC-MS confirmed the O25B polysaccharide structure in the conjugate, opening up the possibility to develop a multivalent E. coli conjugate vaccine containing O25B-EPA.
Identifiants
pubmed: 33730261
doi: 10.1007/s10719-021-09985-9
pii: 10.1007/s10719-021-09985-9
pmc: PMC8260533
doi:
Substances chimiques
Escherichia coli Vaccines
0
Glycoconjugates
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
421-435Références
Kaper, J.B., Nataro, J.P., Mobley, H.L.: Pathogenic Escherichia coli. Nature reviews. 2, 123–140 (2004). https://doi.org/10.1038/nrmicro818
doi: 10.1038/nrmicro818
pubmed: 15040260
Russo, T.A., Johnson, J.R.: Medical and economic impact of extraintestinal infections due to Escherichia coli. focus on an increasingly important endemic problem. Microbes and infection / Institut Pasteur. 5, 449–456 (2003)
doi: 10.1016/S1286-4579(03)00049-2
Rogers, B.A., Sidjabat, H.E., Paterson, D.L.: Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J. Antimicrob. Chemother. 66, 1–14 (2011). https://doi.org/10.1093/jac/dkq415
doi: 10.1093/jac/dkq415
pubmed: 21081548
Coque, T.M., Novais, A., Carattoli, A., Poirel, L., Pitout, J., Peixe, L., Baquero, F., Cantón, R., Nordmann, P.: Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg. Infect. Dis. 14, 195–200 (2008). https://doi.org/10.3201/eid1402.070350
doi: 10.3201/eid1402.070350
pubmed: 18258110
pmcid: 2600198
Nicolas-Chanoine, M.-H., Blanco, J., Leflon-Guibout, V., Demarty, R., Alonso, M.P., Caniça, M.M., Park, Y.-J., Lavigne, J.-P., Pitout, J., Johnson, J.R.: Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. H4-ST131 producing CTX-M-15. J. Antimicrob. Chemother. (2008). https://doi.org/10.1093/jac/dkm464
Johnson, J.R., Johnston, B., Clabots, C., Kuskowski, M.A., Castanheira, M.: Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. (2010). https://doi.org/10.1086/653932
Clermont, O., Lavollay, M., Vimont, S., Deschamps, C., Forestier, C., Branger, C., Denamur, E., Arlet, G.: The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J. Antimicrob. Chemother. 61, 1024–1028 (2008). https://doi.org/10.1093/jac/dkn084
doi: 10.1093/jac/dkn084
pubmed: 18334490
Szijártó, V., Lukasiewicz, J., Gozdziewicz, T.K., Magyarics, Z., Nagy, E., Nagy, G.: Diagnostic potential of monoclonal antibodies specific to the unique O-antigen of multidrug-resistant epidemic Escherichia coli clone ST131-O25b:H4. Clin. Vaccine Immunol. 21, 930–939 (2014). https://doi.org/10.1128/CVI.00685-13
doi: 10.1128/CVI.00685-13
pubmed: 24789798
pmcid: 4097449
Stenutz, R., Weintraub, A., Widmalm, G.: The structures of Escherichia coli O-polysaccharide antigens. FEMS Microbiol. Rev. 30, 382–403 (2006)
doi: 10.1111/j.1574-6976.2006.00016.x
Whitfield, C., Trent, M.S.: Biosynthesis and export of bacterial lipopolysaccharides*. Annu. Rev. Biochem. 83, 99–128 (2014). https://doi.org/10.1146/annurev-biochem-060713-035600
doi: 10.1146/annurev-biochem-060713-035600
pubmed: 24580642
Miajlovic, H., Smith, S.G.: Bacterial self-defence: how Escherichia coli evades serum killing. FEMS Microbiol. Lett. 354, 1–9 (2014). https://doi.org/10.1111/1574-6968.12419
doi: 10.1111/1574-6968.12419
pubmed: 24617921
Poolman, J.T., Wacker, M.: Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and Progress in the field. J. Infect. Dis. 213, 6–13 (2015). https://doi.org/10.1093/infdis/jiv429
doi: 10.1093/infdis/jiv429
pubmed: 26333944
pmcid: 4676548
Vella, M., Pace, D.: Glycoconjugate vaccines: an update. Expert. Opin. Biol. Ther. 15, 529–546 (2015). https://doi.org/10.1517/14712598.2015.993375
doi: 10.1517/14712598.2015.993375
pubmed: 25496172
Szu, S.C.: Development of vi conjugate - a new generation of typhoid vaccine. Expert Rev Vaccines. 12, 1273–1286 (2013). https://doi.org/10.1586/14760584.2013.845529
doi: 10.1586/14760584.2013.845529
pubmed: 24156285
Cross, A., Artenstein, A., Que, J., Fredeking, T., Furer, E., Sadoff, J.C., Cryz Jr., S.J.: Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. J. Infect. Dis. 170, 834–840 (1994)
doi: 10.1093/infdis/170.4.834
Wacker, M., Linton, D., Hitchen, P.G., Nita-Lazar, M., Haslam, S.M., North, S.J., Panico, M., Morris, H.R., Dell, A., Wren, B.W., Aebi, M.: N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science. 298, 1790–1793 (2002)
doi: 10.1126/science.298.5599.1790
Feldman, M.F., Wacker, M., Hernandez, M., Hitchen, P.G., Marolda, C.L., Kowarik, M., Morris, H.R., Dell, A., Valvano, M.A., Aebi, M.: Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 102, 3016–3021 (2005)
doi: 10.1073/pnas.0500044102
Phan, M.-D., Peters, K.M., Sarkar, S., Lukowski, S.W., Allsopp, L.P., Gomes Moriel, D., Achard, Maud E S, Totsika, M., Marshall, V.M., Upton, M., Beatson, S.A., Schembri, M.A.: The serum resistome of a globally disseminated multidrug resistant uropathogenic Escherichia coli clone. PLoS Genet (2013). https://doi.org/10.1371/journal.pgen.1003834
Ravenscroft, N., Haeuptle, M.A., Kowarik, M., Fernandez, F.S., Carranza, P., Brunner, A., Steffen, M., Wetter, M., Keller, S., Ruch, C., Wacker, M.: Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli. Glycobiology. cwv077 (2016). https://doi.org/10.1093/glycob/cwv077
Wacker, M., Wang, L., Kowarik, M., Dowd, M., Lipowsky, G., Faridmoayer, A., Shields, K., Park, S., Alaimo, C., Kelley, K.A., Braun, M., Quebatte, J., Gambillara, V., Carranza, P., Steffen, M., Lee, J.C.: Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli. J. Infect. Dis. 209, 1551–1561 (2014). https://doi.org/10.1093/infdis/jit800
doi: 10.1093/infdis/jit800
pubmed: 24308931
Ihssen, J., Kowarik, M., Dilettoso, S., Tanner, C., Wacker, M., Thony-Meyer, L.: Production of glycoprotein vaccines in Escherichia coli. Microb. Cell Factories. 9, 61 (2010). https://doi.org/10.1186/1475-2859-9-61
doi: 10.1186/1475-2859-9-61
Kowarik, M., Wetter, M., Kemmler, S., Häuptle, M., Gambillara, V., Mally, M.: Polysaccharide and uses thereof Patent US10441647B2
Lee, D.J., Bingle, L.E., Heurlier, K., Pallen, M.J., Penn, C.W., Busby, S.J., Hobman, J.L.: Gene doctoring. a method for recombineering in laboratory and pathogenic Escherichia coli strains. BMC Microbiol. 9, 252 (2009)
doi: 10.1186/1471-2180-9-252
Wacker, M., Kowarik, M., Fernandez, F.: Methods of host cell modification Patent EP3055416B1
Datsenko, K.A., Wanner, B.L.: One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U. S. A. 97, 6640–6645 (2000)
doi: 10.1073/pnas.120163297
Apicella, M.A.: Isolation and characterization of lipopolysaccharides. Methods in molecular biology (Clifton, N.J 431, 3–13 (2008)
Kämpf, M.M., Braun, M., Sirena, D., Ihssen, J., Thöny-Meyer, L., Ren, Q.: In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation. Microb. Cell Factories. 14, 12 (2015). https://doi.org/10.1186/s12934-015-0195-7
doi: 10.1186/s12934-015-0195-7
van den Dobbelsteen, Germie P.J.M., Faé, K.C., Serroyen, J., van den Nieuwenhof, Ingrid M., Braun, M., Haeuptle, M.A., Sirena, D., Schneider, J., Alaimo, C., Lipowsky, G., Gambillara-Fonck, V., Wacker, M., Poolman, J.T.: Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models. Vaccine (2016). https://doi.org/10.1016/j.vaccine.2016.06.067
Wetter, M., Kowarik, M., Steffen, M., Carranza, P., Corradin, G., Wacker, M.: Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component. Glycoconj. J. 30, 511–522 (2013). https://doi.org/10.1007/s10719-012-9451-9
doi: 10.1007/s10719-012-9451-9
pubmed: 23053636
Kim, J.S., Laskowich, E.R., Arumugham, R.G., Kaiser, R.E., MacMichael, G.J.: Determination of saccharide content in pneumococcal polysaccharides and conjugate vaccines by GC-MSD. Anal. Biochem. 347, 262–274 (2005). https://doi.org/10.1016/j.ab.2005.09.022
doi: 10.1016/j.ab.2005.09.022
pubmed: 16266683
Beczała, A., Duda, K.A., Skurnik, M., Holst, O.: The structure of the O-specific polysaccharide of the lipopolysaccharide from Yersinia enterocolitica serotype O:50 strain 3229. Carbohydr. Res. 359, 97–101 (2012). https://doi.org/10.1016/j.carres.2012.06.002
doi: 10.1016/j.carres.2012.06.002
pubmed: 22925771
Gerwig, G.J., Kamerling, J.P., Vliegenthart, J.F.G.: Determination of the d and l configuration of neutral monosaccharides by high-resolution capillary g.l.c. Carbohydr Res (1978). https://doi.org/10.1016/S0008-6215(00)80881-2
Gerwig, G.J., Kamerling, J.P., Vliegenthart, J.F.: Determination of the absolute configuration of mono-saccharides in complex carbohydrates by capillary G.L.C. Carbohydr. Res. 77, 10–17 (1979)
doi: 10.1016/S0008-6215(00)83788-X
Harris, P.J., Henry, R.J., Blakeney, A.B., Stone, B.A.: An improved procedure for the methylation analysis of oligosaccharides and polysaccharides. Carbohydr. Res. 127, 59–73 (1984)
doi: 10.1016/0008-6215(84)85106-X
Albersheim, P., Nevins, D.J., English, P.D., Karr, A.: A method for the analysis of sugars in plant cell-wall polysaccharides by gas-liquid chromatography. Carbohydr. Res. 5, 340–345 (1967). https://doi.org/10.1016/S0008-6215(00)80510-8
doi: 10.1016/S0008-6215(00)80510-8
Sweet, D.P., Shapiro, R.H., Albersheim, P.: Quantitative analysis by various g.l.c. response-factor theories for partially methylated and partially ethylated alditol acetates. Carbohydr Res (1975). https://doi.org/10.1016/S0008-6215(00)82604-X
Gottlieb, H.E., Kotlyar, V., Nudelman, A.: NMR chemical shifts of common laboratory solvents as trace impurities. J. Organic Chem. 62, 7512–7515 (1997)
doi: 10.1021/jo971176v
Kenne, L., Lindberg, B., Madden, J.K., Lindberg, A.A., Gemski, P.: Structural studies of the Escherichia coli O-antigen 25. Carbohydr. Res. 122, 249–256 (1983)
doi: 10.1016/0008-6215(83)88336-0
Lundborg, C., Westerlund, A., Bjorklund, U., Biber, B., Hansson, E.: Ifenprodil restores GDNF-evoked Ca(2+) signalling and Na(+)/K(+) -ATPase expression in inflammation-pretreated astrocytes. J. Neurochem. 119, 686–696 (2011). https://doi.org/10.1111/j.1471-4159.2011.07465.x
doi: 10.1111/j.1471-4159.2011.07465.x
pubmed: 21883228
Stevenson, G., Neal, B., Liu, D., Hobbs, M., Packer, N.H., Batley, M., Redmond, J.W., Lindquist, L., Reeves, P.: Structure of the O antigen of Escherichia coli K-12 and the sequence of its rfb gene cluster. J. Bacteriol. 176, 4144–4156 (1994)
doi: 10.1128/jb.176.13.4144-4156.1994
K.R. Talaat, C. Alaimo, A.L. Bourgeois, R.W. Kaminski, A. Dreyer, C.K. Porter, S. Chakraborty, K. A. Clarkson, J. Brubaker, D. Elwood, R. Frölich, B. DeNearing, H. Weerts, B. Feijoo, D. Sack, M.S. Riddle, P. Martin, V. Gambillara Fonck: Flexyn2a, a candidate bioconjugate vaccine against shigella flexneri 2a induces protective immune response in a controlled human infection model. Vaccines for enteric diseases, Albufeira, (2017)
Hatz, C., Bally, B., Rohrer, S., Steffen, R., Kramme, S., Siegrist, C.-A., Wacker, M., Alaimo, C., Fonck, V.G.: Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: a single blind, partially randomized phase I study. Vaccine. 33, 4594–4601 (2015). https://doi.org/10.1016/j.vaccine.2015.06.102
doi: 10.1016/j.vaccine.2015.06.102
pubmed: 26162850
Huttner, A., Hatz, C., van den Dobbelsteen, Germie, Abbanat, D., Hornacek, A., Frölich, R., Dreyer, A.M., Martin, P., Davies, T., Fae, K., van den Nieuwenhof, Ingrid, Thoelen, S., de Vallière, S., Kuhn, A., Bernasconi, E., Viereck, V., Kavvadias, T., Kling, K., Ryu, G., Hülder, T., Gröger, S., Scheiner, D., Alaimo, C., Harbarth, S., Poolman, J., Fonck, V.G.: Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. The Lancet Infectious Diseases (2017). https://doi.org/10.1016/S1473-3099(17)30108-1
Inoue, M., Ogawa, T., Tamura, H., Hagiwara, Y., Saito, Y., Abbanat, D., van den Dobbelsteen, Germie, Hermans, P., Thoelen, S., Poolman, J., de Palacios, Patricia Ibarra: Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive Extraintestinal pathogenic Escherichia coli disease: a phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants. Hum Vaccin Immunother (2018). https://doi.org/10.1080/21645515.2018.1474316
Frenck, R.W., Ervin, J., Chu, L., Abbanat, D., Spiessens, B., Go, O., Haazen, W., van den Dobbelsteen, Germie, Poolman, J., Thoelen, S., Ibarra de Palacios, P.: Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial. The Lancet Infectious Diseases (2019). https://doi.org/10.1016/S1473-3099(18)30803-X
van den Dobbelsteen, G.P., van Dijken, H.H., Pillai, S., van Alphen, L.: Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine. 25, 2491–2496 (2007). https://doi.org/10.1016/j.vaccine.2006.09.025
doi: 10.1016/j.vaccine.2006.09.025
pubmed: 17023098